Maiwei Biotech: The clinical trial application for 6MW5311 for injection for the indications of hematologic malignancies, chronic myelomonocytic leukemia and multiple myeloma has been officially approved by the FDA.
2026-06-12
Maiwei Biotech: The clinical trial application for 6MW5311 for injection for the indications of hematologic malignancies, chronic myelomonocytic leukemia and multiple myeloma has been officially approved by the FDA.